NASDAQ:DXCM DexCom Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding DexCom, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $386.07 -12.06 (-3.03 %) (As of 09/23/2020 12:00 AM ET) Add Compare Share Today's Range$382.62Now: $386.07▼$398.5150-Day Range$383.46MA: $415.09▼$451.7952-Week Range$145.23Now: $386.07▼$456.23Volume543,567 shsAverage Volume1.29 million shsMarket Capitalization$36.96 billionP/E Ratio176.29Dividend YieldN/ABeta0.81 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop a series of next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.Read More Beat the Market (BTM) Rank™ 2.4 Analyst's Opinion Consensus RatingDexCom has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 15 buy ratings, 5 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $403.89, DexCom has a forecasted upside of 4.6% from its current price of $386.07.Amount of Analyst CoverageDexCom has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Community Rank Outperform VotesDexCom has received 871 “outperform” votes. (Add your “outperform” vote.)Underperform VotesDexCom has received 575 “underperform” votes. (Add your “underperform” vote.)Community SentimentDexCom has received 60.24% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about DexCom and other stocks. Vote “Outperform” if you believe DXCM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe DXCM will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldDexCom does not currently pay a dividend.Dividend GrowthDexCom does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, DexCom insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $21,784,204.00 in company stock.Percentage Held by InsidersOnly 0.69% of the stock of DexCom is held by insiders.Percentage Held by Institutions97.51% of the stock of DexCom is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for DexCom are expected to grow by 24.34% in the coming year, from $2.67 to $3.32 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of DexCom is 176.29, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 17.54.Price to Earnings Ratio vs. SectorThe P/E ratio of DexCom is 176.29, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 21.35.Price to Earnings Growth RatioDexCom has a PEG Ratio of 3.90. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioDexCom has a P/B Ratio of 40.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 2.4Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.53 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNASDAQ:DXCM Previous Symbol CUSIP25213110 CIK1093557 Webwww.dexcom.com Phone858-200-0200Debt Debt-to-Equity Ratio1.23 Current Ratio7.58 Quick Ratio7.17Price-To-Earnings Trailing P/E Ratio176.29 Forward P/E Ratio144.60 P/E Growth3.9 Sales & Book Value Annual Sales$1.48 billion Price / Sales25.04 Cash Flow$2.34 per share Price / Cash Flow164.65 Book Value$9.64 per share Price / Book40.05Profitability EPS (Most Recent Fiscal Year)$1.84 Net Income$101.10 million Net Margins11.93% Return on Equity29.01% Return on Assets10.82%Miscellaneous Employees3,900 Outstanding Shares95,742,000Market Cap$36.96 billion Next Earnings Date11/4/2020 (Estimated) OptionableOptionable $386.07 -12.06 (-3.03 %) (As of 09/23/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive DXCM News and Ratings via Email Sign-up to receive the latest news and ratings for DXCM and its competitors with MarketBeat's FREE daily newsletter. DexCom (NASDAQ:DXCM) Frequently Asked Questions How has DexCom's stock been impacted by Coronavirus? DexCom's stock was trading at $252.42 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, DXCM stock has increased by 52.9% and is now trading at $386.07. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of DexCom? 20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last year. There are currently 5 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for DexCom. When is DexCom's next earnings date? DexCom is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020. View our earnings forecast for DexCom. How were DexCom's earnings last quarter? DexCom, Inc. (NASDAQ:DXCM) posted its quarterly earnings results on Tuesday, July, 28th. The medical device company reported $0.79 earnings per share for the quarter, beating the consensus estimate of $0.31 by $0.48. The medical device company earned $451.80 million during the quarter, compared to the consensus estimate of $415.21 million. DexCom had a return on equity of 29.01% and a net margin of 11.93%. The company's quarterly revenue was up 34.3% on a year-over-year basis. During the same period in the previous year, the company posted $0.08 earnings per share. View DexCom's earnings history. What guidance has DexCom issued on next quarter's earnings? DexCom updated its FY 2020 After-Hours earnings guidance on Tuesday, July, 28th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.85-1.85 billion, compared to the consensus revenue estimate of $1.8 billion. What price target have analysts set for DXCM? 20 analysts have issued 1-year target prices for DexCom's shares. Their forecasts range from $200.00 to $500.00. On average, they expect DexCom's share price to reach $403.89 in the next year. This suggests a possible upside of 4.6% from the stock's current price. View analysts' price targets for DexCom. Who are some of DexCom's key competitors? Some companies that are related to DexCom include Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Stryker (SYK), Becton Dickinson and (BDX), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), IDEXX Laboratories (IDXX), ResMed (RMD), Hologic (HOLX), Varian Medical Systems (VAR), Teleflex (TFX), Insulet (PODD) and Steris (STE). View all competitors. What other stocks do shareholders of DexCom own? Based on aggregate information from My MarketBeat watchlists, some companies that other DexCom investors own include NVIDIA (NVDA), Alibaba Group (BABA), Paypal (PYPL), Netflix (NFLX), Tesla (TSLA), salesforce.com (CRM), Trade Desk (TTD), Walt Disney (DIS), Shopify (SHOP) and Advanced Micro Devices (AMD). Who are DexCom's key executives? DexCom's management team includes the following people: Mr. Kevin R. Sayer, Exec. Chairman, CEO & Pres (Age 61)Mr. Quentin S. Blackford, Exec. VP & CFO (Age 40)Mr. Steven R. Pacelli, Exec. VP of Strategy & Corp. Devel. (Age 47)Mr. Andrew K. Balo, Exec. VP of Clinical Affairs, Regulatory Strategies & Global Access (Age 71)Mr. Richard B. Doubleday, Exec. VP & Chief Commercial Officer (Age 56) What is DexCom's stock symbol? DexCom trades on the NASDAQ under the ticker symbol "DXCM." Who are DexCom's major shareholders? DexCom's stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (10.73%), Mint Tower Capital Management B.V. (8.20%), Jennison Associates LLC (2.88%), Blair William & Co. IL (1.12%), GQG Partners LLC (0.63%) and Federated Hermes Inc. (0.61%). Company insiders that own DexCom stock include Andrew K Balo, Barbara Kahn, Donald Abbey, Heather S Ace, Jacob Steven Leach, Jeffrey Moy, Jereme M Sylvain, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Quentin S Blackford, Richard Alexander Collins, Richard Doubleday, Shelly Ramasamy Selvaraj, Steven R Altman and Steven Robert Pacelli. View institutional ownership trends for DexCom. Which institutional investors are selling DexCom stock? DXCM stock was sold by a variety of institutional investors in the last quarter, including Zurcher Kantonalbank Zurich Cantonalbank, Holocene Advisors LP, Columbus Circle Investors, Ardevora Asset Management LLP, Neuberger Berman Group LLC, Frontier Capital Management Co. LLC, Orbimed Advisors LLC, and Sumitomo Mitsui Trust Holdings Inc.. Company insiders that have sold DexCom company stock in the last year include Andrew K Balo, Barbara Kahn, Donald Abbey, Heather S Ace, Jacob Steven Leach, Jeffrey Moy, Jereme M Sylvain, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Quentin S Blackford, Richard Alexander Collins, Richard Doubleday, Shelly Ramasamy Selvaraj, Steven R Altman, and Steven Robert Pacelli. View insider buying and selling activity for DexCom. Which institutional investors are buying DexCom stock? DXCM stock was purchased by a variety of institutional investors in the last quarter, including Mint Tower Capital Management B.V., Vanguard Group Inc., Charles Schwab Investment Management Inc., Coatue Management LLC, GQG Partners LLC, Principal Financial Group Inc., Principal Financial Group Inc., and New York State Teachers Retirement System. View insider buying and selling activity for DexCom. How do I buy shares of DexCom? Shares of DXCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is DexCom's stock price today? One share of DXCM stock can currently be purchased for approximately $386.07. How big of a company is DexCom? DexCom has a market capitalization of $36.96 billion and generates $1.48 billion in revenue each year. The medical device company earns $101.10 million in net income (profit) each year or $1.84 on an earnings per share basis. DexCom employs 3,900 workers across the globe. What is DexCom's official website? The official website for DexCom is www.dexcom.com. How can I contact DexCom? DexCom's mailing address is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. The medical device company can be reached via phone at 858-200-0200 or via email at [email protected] This page was last updated on 9/24/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
